A Clinical Study to Assess the Feasibility of a Controlled Human Plasmodium Vivax Malaria Infection Model Through Sporozoite Infection in Thai Adults

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is a human challenge study to assess the feasibility and safety of controlled human malaria infection (via P. vivax sporozites) in healthy volunteers, and to develop a bank of P. vivax-infected blood for use in future controlled human P. vivax malaria infection studies. Additional objectives are to obtain data on host immune response to P. vivax infection and pre-treatment gametocytaemia. This study is funded by the UK Wellcome Trust. The grant reference number are Oxford/MORU: 212336/Z/18/Z and 212336/Z/18/A, and Mahidol University: 212336/A/18/Z and 212336/A/18/A.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 55
Healthy Volunteers: t
View:

• Healthy adult aged 20 to 55 years with weight more than 50 kg.

• Blood group O.

• Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).

• Normal CYP2D6 genotype.

• Normal blood levels of Glucose-6-phosphate dehydrogenase (G6PDH) by the WHO definition.

• COVID-19 vaccination at least two doses of COVID-19 vaccine(s) approved by WHO.

• Agree to practice continuous effective contraception for the duration of study period until 3 months post-challenge.

• Agreement to refrain from blood donation during the course of the study and for 1 year after the end of their involvement in the study.

• Willing to take a curative antimalarial regimen following challenge.

• Willing to be admitted in the Hospital for Tropical Diseases for blood donation and clinical monitoring, until antimalarial treatment is completed and their symptoms are settling.

• Willing to reside in Bangkok for the duration of the study, until all antimalarial treatment has been completed.

• Reachable (24/7) by mobile phone during the period between challenge CHMI and completion of all antimalarial treatment.

• Able to read and write in Thai and able to answer ALL questions on the informed consent questionnaire correctly.

• Provided written informed consent to participate in the trial.

• Educational level: has at least an undergraduate degree.

• Cardiovascular risk assessment is low (less than 10% in the next 10 years according to the cardiovascular risk assessment from Thai NCD Division, DDC, MoPH (2016)

Locations
Other Locations
Thailand
Faculty of Tropical Medicine
RECRUITING
Bangkok
Contact Information
Primary
Nicholas Day, MD
nickd@tropmedres.ac
+66-(0)2-3549170
Backup
Jetsumon Sattabongkot Prachumsri, Ph.D
jetsumon.pra@mahidol.ac.th
+66-(0)2-3549100
Time Frame
Start Date: 2020-10-05
Estimated Completion Date: 2025-09-30
Participants
Target number of participants: 6
Treatments
Experimental: Malaria challenge
Malaria Sporozoite Challenge by mosquito bites.
Related Therapeutic Areas
Sponsors
Collaborators: Mahidol University
Leads: University of Oxford

This content was sourced from clinicaltrials.gov